Vir Biotechnology Inc (VIR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vir Biotechnology Inc (VIR) has a cash flow conversion efficiency ratio of -0.163x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-132.39 Million) by net assets ($812.76 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See VIR net asset quality score to measure how much of total assets are equity-financed.
Vir Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Vir Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Vir Biotechnology Inc to evaluate the quality of earnings relative to operating cash generation.
Vir Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vir Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Fenglong Electric Co Ltd Class A
SHE:002931
|
0.012x |
|
Minera Valparaiso S.A.
SN:MINERA
|
0.026x |
|
Playa Hotels & Resorts BV
F:PL0
|
0.147x |
|
Wizz Air Holdings Plc
F:WI2
|
N/A |
|
Zhejiang Construction Investment Group Co Ltd
SHE:002761
|
0.029x |
|
Innovative Industrial Properties Inc
NYSE:IIPR
|
0.024x |
|
Exail Technologies S.A.
PA:EXA
|
0.102x |
|
Shenzhen Bluetrum Technology Co. Ltd. A
SHG:688332
|
N/A |
Annual Cash Flow Conversion Efficiency for Vir Biotechnology Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Vir Biotechnology Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see VIR company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $765.28 Million | $-391.78 Million | -0.512x | -31.94% |
| 2024-12-31 | $1.15 Billion | $-446.35 Million | -0.388x | +20.77% |
| 2023-12-31 | $1.59 Billion | $-778.78 Million | -0.490x | -161.18% |
| 2022-12-31 | $2.08 Billion | $1.66 Billion | 0.800x | +2508.30% |
| 2021-12-31 | $1.43 Billion | $-47.59 Million | -0.033x | +87.52% |
| 2020-12-31 | $716.85 Million | $-190.94 Million | -0.266x | +12.89% |
| 2019-12-31 | $423.94 Million | $-129.63 Million | -0.306x | -158.23% |
| 2018-12-31 | $-179.18 Million | $-94.10 Million | 0.525x | -45.48% |
| 2017-12-31 | $-68.92 Million | $-66.38 Million | 0.963x | -- |
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those ta… Read more